Download the 2018 Agenda
Solve The Challenges Of Launching And Maintaining Early And Managed Access Programmes, Navigate The Complex Regulatory Landscape And Hear The Patient’s Voice!Join us 22nd - 24th October 2018, where industry leaders from Janssen,
Leveraging Real World Data From Early Access Programmes
One of the key benefits of Early Access Programmes is that they allow companies to collect real world data from patients within the programme, which can help inform a product’s effectiveness and value proposition. With insights from Tom Watson, Executive Vice President, Early Access Progra ...
Five Key Considerations for Early Access Programmes
Embarking on an Early Access Programme is challenging due to a number of factors, including navigating the complex regulatory landscape and the modality of providing access to patients. Ahead of her participation in the upcoming Early and Managed Access Programmes Forum, we spoke exclusively to A ...
Top 6 Factors To Consider In Your Forecasting Strategy
Pharmaceutical specialists, Dr. Carlos R. Camozzi and Ramana Sonty spoke to Pharma IQ in regards to the top 6 factors to consider in an early access programme planning strategy.
Early Access Programmes: Regulation Handbook - 2nd Edition
Ahead of this year’s Early Access Programmes Europe conference, Pharma IQ expands its regulatory handbook to develop the industry’s awareness of the various compliance requirements that surround the implementation of these programmes.
Facing The Ethical Minefield: Early Access Programmes
There are numerous ethical landmines for pharmaceutical companies to consider and navigate in running Early Access Programmes. Ahead of this year's conference, Pharma IQ spoke to Arthur Caplan, Head of Bioethics, New York University Langone Medical Center and Chairman, of the C ...
Early Access Programmes: Regulatory Handbook
This Pharma IQ handbook showcases the main regulatory requirements to be considered in regards to early access programmes within the EU. Including specific requirements for Austria, Denmark, France, Germany, Italy, Spain, Sweden, Switzerland, and the UK.
Early Access Programmes: Challenges and Considerations
In this Pharma IQ interview, Jose Ricardo Perez, Senior Medical Director at Novartis,highlights the biggest considerations for someone potentially looking at a new early access programme (EAP) and the key regulatory differences between the USA and Europe. Perez also reveals his top tips for someo ...
Five minutes with Vee Mapunde on: the growing influence of patient advocacy groups in Early Access Programmes
We had a chat with Vee Mapunde, Associate Consumer Lead at the National Cancer Research Institute (NCRI) on the role of patient advocacy groups in the Early Access Prorammes landscape, their missions and the tools they have to fulfill them, ahead of the Early and Managed Access Programmes confere ...
Three tips to ensure an ethical and sustainable Early Access Programme
Early and Managed Access Programmes can prolong the life of patients who have a life-threatening illness or a chronic or rare condition, by providing them access to investigational drugs. Their investigative nature does mean that ethical challenges often arise during their process. With this in m ...
Additional Content Download
Managed Access Programs: Reaching Patients in Need
Navigating the MAP: Durbin offers the regulatory expertise, and vast distribution networks, to get the most out of a Managed Access Program for both patients and Biotech/ Pharmaceutical companies. Read more here.